ANI Pharmaceuticals (NASDAQ:ANIP) Director Sells $146,070.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Director Renee Tannenbaum sold 1,800 shares of the company’s stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $81.15, for a total transaction of $146,070.00. Following the sale, the director directly owned 25,157 shares in the company, valued at approximately $2,041,490.55. This trade represents a 6.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

ANI Pharmaceuticals Stock Performance

Shares of ANI Pharmaceuticals stock traded up $0.33 during trading hours on Tuesday, reaching $81.67. The company had a trading volume of 232,431 shares, compared to its average volume of 376,402. ANI Pharmaceuticals, Inc. has a one year low of $52.50 and a one year high of $99.50. The firm has a market cap of $1.84 billion, a PE ratio of 50.10 and a beta of 0.48. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.58 and a quick ratio of 2.04. The business has a fifty day simple moving average of $88.29 and a 200 day simple moving average of $80.19.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.74 by $0.30. ANI Pharmaceuticals had a net margin of 4.91% and a return on equity of 26.73%. The business had revenue of $227.81 million for the quarter, compared to the consensus estimate of $211.92 million. During the same period last year, the firm posted $1.34 earnings per share. ANI Pharmaceuticals’s quarterly revenue was up 53.6% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. On average, analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current fiscal year.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the company. Advisors Asset Management Inc. bought a new stake in shares of ANI Pharmaceuticals during the 1st quarter valued at about $28,000. Hantz Financial Services Inc. lifted its stake in shares of ANI Pharmaceuticals by 202.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock worth $32,000 after purchasing an additional 237 shares during the period. Caitong International Asset Management Co. Ltd boosted its holdings in shares of ANI Pharmaceuticals by 4,636.4% in the second quarter. Caitong International Asset Management Co. Ltd now owns 521 shares of the specialty pharmaceutical company’s stock worth $34,000 after buying an additional 510 shares during the last quarter. Newbridge Financial Services Group Inc. grew its position in ANI Pharmaceuticals by 200.0% during the second quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company’s stock valued at $39,000 after buying an additional 400 shares during the period. Finally, State of Wyoming bought a new stake in ANI Pharmaceuticals during the second quarter valued at approximately $50,000. 76.05% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Weiss Ratings reiterated a “buy (b-)” rating on shares of ANI Pharmaceuticals in a report on Monday. Zacks Research raised ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 21st. Truist Financial lifted their price target on shares of ANI Pharmaceuticals from $77.00 to $90.00 and gave the company a “hold” rating in a report on Thursday, October 9th. JPMorgan Chase & Co. upped their price objective on shares of ANI Pharmaceuticals from $95.00 to $115.00 and gave the stock an “overweight” rating in a report on Wednesday, September 24th. Finally, HC Wainwright lifted their target price on shares of ANI Pharmaceuticals from $93.00 to $121.00 and gave the company a “buy” rating in a research note on Wednesday, September 17th. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $99.38.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.